Sigma Planning Corp Boosts Stake in Cue Biopharma, Inc. (NASDAQ:CUE)

Sigma Planning Corp lifted its stake in Cue Biopharma, Inc. (NASDAQ:CUE) by 50.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 401,325 shares of the company’s stock after purchasing an additional 135,295 shares during the quarter. Sigma Planning Corp’s holdings in Cue Biopharma were worth $304,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in Cue Biopharma in the 2nd quarter valued at approximately $66,000. Good Life Advisors LLC increased its stake in shares of Cue Biopharma by 23.1% during the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after buying an additional 75,000 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Cue Biopharma by 7.1% in the first quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock valued at $4,316,000 after acquiring an additional 150,457 shares in the last quarter. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Stifel Nicolaus dropped their price objective on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Piper Sandler dropped their target price on Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating on the stock in a report on Friday, July 26th. Finally, JMP Securities cut their price target on Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating on the stock in a research note on Friday, July 26th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Cue Biopharma has a consensus rating of “Buy” and an average price target of $5.00.

Cue Biopharma Trading Down 17.0 %

Shares of Cue Biopharma stock opened at $1.25 on Friday. The company has a fifty day simple moving average of $1.14 and a 200-day simple moving average of $1.16. Cue Biopharma, Inc. has a 12-month low of $0.45 and a 12-month high of $3.25. The company has a current ratio of 2.06, a quick ratio of 2.06 and a debt-to-equity ratio of 0.11. The stock has a market cap of $60.56 million, a price-to-earnings ratio of -1.28 and a beta of 1.80.

Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.09. Cue Biopharma had a negative return on equity of 142.93% and a negative net margin of 566.02%. The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $1.12 million. During the same quarter last year, the company posted ($0.29) earnings per share. On average, equities analysts forecast that Cue Biopharma, Inc. will post -0.73 EPS for the current fiscal year.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.